Gabriella Hobbs, MD, Massachusetts General Hospital, Boston, MA, discusses the significance of asciminib, a new TKI treatment for patients with CML. She also stresses the need for patients with CML to achieve deep remission that leads to the discontinuation of TKI therapy.